Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis

BACKGROUND: Fexuprazan, a novel potassium-competitive acid blocker, reversibly suppresses the K(+)/H(+)-ATPase enzyme in proton pumps within gastric parietal cells. Fexuprazan’s suppression of gastric acid was maintained in healthy individuals for 24 h in a dose-dependent manner. AIM: To compare fex...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kang Nyeong, Lee, Oh Young, Chun, Hoon Jai, Kim, Jin Il, Kim, Sung Kook, Lee, Sang Woo, Park, Kyung Sik, Lee, Kook Lae, Choi, Suck Chei, Jang, Jae-Young, Kim, Gwang Ha, Sung, In-kyung, Park, Moo In, Kwon, Joong Goo, Kim, Nayoung, Kim, Jae Jun, Lee, Soo Teik, Kim, Hyun Soo, Kim, Ki Bae, Lee, Yong Chan, Choi, Myung-Gyu, Lee, Joon Seong, Jung, Hwoon-Yong, Lee, Kwang Jae, Kim, Jie-Hyun, Chung, Hyunsoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Randomized Controlled Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730436/
https://www.ncbi.nlm.nih.gov/pubmed/36504556
http://dx.doi.org/10.3748/wjg.v28.i44.6294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730436/
https://www.ncbi.nlm.nih.gov/pubmed/36504556
http://dx.doi.org/10.3748/wjg.v28.i44.6294

Ejemplares similares